Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
2010 1
2011 1
2012 1
2013 2
2014 1
2016 1
2017 2
2019 1
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.
Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S. Serrano C, et al. Among authors: carreras mj. Ann Oncol. 2019 Jul 1;30(7):1178. doi: 10.1093/annonc/mdy534. Ann Oncol. 2019. PMID: 30624599 Free article. No abstract available.
Pancreatic cancer heterogeneity and response to Mek inhibition.
Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J. Pedersen K, et al. Among authors: carreras mj. Oncogene. 2017 Oct 5;36(40):5639-5647. doi: 10.1038/onc.2017.174. Epub 2017 Jun 5. Oncogene. 2017. PMID: 28581516
A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases.
Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J. Tabernero J, et al. Among authors: carreras mj. Clin Cancer Res. 2014 May 15;20(10):2793-804. doi: 10.1158/1078-0432.CCR-13-1837. Epub 2014 Mar 14. Clin Cancer Res. 2014. PMID: 24634378 Free article. Clinical Trial.
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.
Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S. Serrano C, et al. Among authors: carreras mj. Ann Oncol. 2012 Apr;23(4):897-902. doi: 10.1093/annonc/mdr348. Epub 2011 Aug 9. Ann Oncol. 2012. PMID: 21828361 Free article.
Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S, Tabernero J, Schwartz S Jr, Arango D. Dopeso H, et al. Among authors: carreras mj. Clin Cancer Res. 2010 Apr 15;16(8):2375-82. doi: 10.1158/1078-0432.CCR-09-3275. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371676 Free article.
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras MJ, Baselga J, Tabernero J. Eskens FA, et al. Among authors: carreras mj. Clin Cancer Res. 2013 Nov 15;19(22):6296-304. doi: 10.1158/1078-0432.CCR-13-0485. Epub 2013 Aug 27. Clin Cancer Res. 2013. PMID: 23983259 Free article. Clinical Trial.
A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
Capdevila J, Clive S, Casado E, Michie C, Piera A, Sicart E, Carreras MJ, Coronado C, Kahatt C, Soto Matos-Pita A, Fernandez Teruel C, Siguero M, Cullell-Young M, Tabernero J. Capdevila J, et al. Among authors: carreras mj. Cancer Chemother Pharmacol. 2013 May;71(5):1247-54. doi: 10.1007/s00280-013-2119-8. Epub 2013 Mar 2. Cancer Chemother Pharmacol. 2013. PMID: 23455428 Clinical Trial.
13 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page